Despite major improvements in the prevention and treatment of HIV, the prevalence of individuals living with and becoming infected by the disease remains unacceptably high. One proposed prevention strategy currently being explored is the use of pre-exposure prophylaxis (PrEP).
The idea underlying PrEP is straightforward - individuals would use existing HIV drug treatments as a prophylaxis against HIV infection. However, in addition to understanding the efficacy of these drug therapies, it is also necessary to begin an examination of how the results of the PrEP trials can be integrated into a comprehensive, global HIV prevention strategy. Researchers have noted that “public-health decisionmakers need to start contingency planning now” to prepare for the impending results of the PrEP clinical trials.
To that end, the O'Neill Institute sponsored a Bill & Melinda Gates Foundation-funded Planning for PrEP Conference in London, United Kingdom in June 2009. The conference served as a launching point to organize critical thought on the impending results of the ongoing PrEP trials. Participants included experts in the field of HIV/AIDS research, key policymakers, and representatives from NGOs.
June 18-19, 2009: “Planning for PrEP” conference, sponsored by the Bill & Melinda Gates Foundation held in London, United Kingdom with approximately thirty stakeholders working on issues relevant to PrEP throughout the world.
Kim, Susan C., Stephen Becker, Carl Dieffenbach, Blair S. Hanewall, Catherine Hankins, Ying-Ru Lo, John W. Mellors, Kevin O’Reilly, Lynn Paxton, Jason S. Roffenbender, Peter Piot, Mitchell Warren, and Mark R. Dybul. "Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities." Journal of the International AIDS Society 13 (2010): 24.
Jones, Alexandra, Ide Cremin, Fareed Abdullah, John Idoko, Peter Cherutich, Nduku Kilonzo, Helen Rees, Kevin O'Reilly, Bernhard Schwartlander, Barbara de Zalduondo, Susan C Kim, Jonathan Jay, Jacqueline Huh, Peter Piot, and Mark Dybul. "Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention." The Lancet doi:10.1016/S0140-6736(13)62230-8 (2014).